Loyal portfolio

Insybio logo

Insybio

Healthcare / Medical / Biomed · USA

Follow OnUSAINSEADSDG 3
Konstantinos TheofilatosL

Konstantinos Theofilatos · Labros Digonis

About Insybio

We drive innovation in both clinical trials and drug discovery and, through our proprietary AI empowered platform, are a leading company in targeted biomarker discovery for fields such as Cancer, Nutrition, Infectious and Neurodegenerative diseases. Through this we enable precision medicine.

Visit website

In the news

  • Sep 25

    InSyBio launches fixed-price micro-analysis packages for RNA-seq, proteomics, biomarker, and machine-learning datasets.

    View on LinkedIn
  • Sep 24

    InSyBio offers Interact for protein-interaction analysis, network visualization, clustering, enrichment, and custom datasets with a free month.

    Read more
  • Sep 24

    InSyBio explains how network context turns protein lists into testable biological hypotheses.

    Read more
  • Sep 24

    InSyBio introduces Interact, connecting predicted protein interactions, protein information, and confidence scores in one workflow.

    Read more
  • Sep 23

    InSyBio adds BioInfoLLM guidance to its Suite, enabling natural-language workflow navigation and evidence-grounded interpretation.

    Read more
  • Sep 23

    InSyBio presents Pipelines, integrating biomedical analysis, biomarker discovery, network analytics, and predictive modeling.

    View on LinkedIn

Founders

  • Konstantinos Theofilatos

    Konstantinos Theofilatos

  • L

    Labros Digonis

Details

Stage
Follow On
Sector
Healthcare / Medical / Biomed, AI / Machine Learning
Country
USA
Region
USA
Source
INSEAD
UN SDGs
SDG 3